Drug intelligence / Profile preview

sym026

Development stage: Preclinical
Lead developer: Symphogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Sym026 is a monoclonal antibody in development for the treatment of neoplasms (cancers). It is being developed by Symphogen A/S and now managed by Les Laboratoires Servier SAS. The specific target and mechanism of action have not been publicly disclosed. Sym026 is currently in the late discovery phase as part of Symphogen’s immuno-oncology pipeline[1][2].

Beyond the preview

Go deeper on sym026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sym026.

Explore the full profile